Head-To-Head Contrast: Forte Biosciences (NASDAQ:FBRX) & PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Insider & Institutional Ownership

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

PDS Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PDS Biotechnology and Forte Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1	0	2	0	2.33
Forte Biosciences	1	4	1	0	2.00

PDS Biotechnology presently has a consensus price target of $9.00, suggesting a potential upside of 4,018.99%. Forte Biosciences has a consensus price target of $71.67, suggesting a potential downside of 6.83%. Given PDS Biotechnology’s stronger consensus rating and higher probable upside, equities research analysts plainly believe PDS Biotechnology is more favorable than Forte Biosciences.

Profitability

This table compares PDS Biotechnology and Forte Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Forte Biosciences	N/A	-94.82%	-77.68%

Valuation and Earnings

This table compares PDS Biotechnology and Forte Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50 million	($0.64)	-0.34
Forte Biosciences	N/A	N/A	-$69.38 million	($4.65)	-16.54

Forte Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

PDS Biotechnology beats Forte Biosciences on 7 of the 11 factors compared between the two stocks.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.